Amerikanische Gesellschaft für Hirudotherapie

Life without blood: Molecular and functional analysis of hirudins and hirudin-like factors of the Asian non-hematophagous leech Whitmania pigra

Comparative biochemistry published in J Thromb Haemost (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologieGenomik & ProteomikMüller C et al. · Journal of thrombosis and haemostasis : JTH, 2022

Abstract

BACKGROUND: Several leech species of the genera Hirudo, Hirudinaria, and Whitmania are widely used in traditional Chinese medicine (TCM) for the oral treatment of disorders associated with blood stasis. Among them, the non-hematophagous leech Whitmania pigra expresses a variety of components that have the potential to act on the vertebrate blood coagulation system. OBJECTIVE: Whether the thrombin inhibitor hirudin, probably the most prominent leech-derived anticoagulant, is actually present in Whitmania pigra, is still a matter of debate. To answer that open question was the aim of the study. METHODS: We identified several putative hirudin-encoding sequences in transcriptome data of Whitmania pigra. Upon gene synthesis and molecular cloning the respective recombinant proteins were expressed in Escherichia coli, purified, processed, and eventually functionally characterized for thrombin-inhibitory potencies in coagulation assays. RESULTS: We were successful in the identification and functional characterization of several putative hirudins in Whitmania pigra. Some, but not all, of these factors are indeed thrombin inhibitors. Whitmania pigra hence expresses both hirudins (factors that inhibit thrombin) and hirudin-like factors (that do not or only very weakly inhibit thrombin). Furthermore, we revealed the exon/intron structures of the corresponding genes. Coding sequences of some putative hirudins of Whitmania pigra were present also in transcriptome datasets of Hirudo nipponia, a hematophagous leech that is likewise used in TCM. CONCLUSIONS: Based on both structural and functional data we provide very strong evidence for the expression of hirudins in Whitmania pigra. This is the first description of hirudins in a non-hematophagous leech.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsBlood CoagulationHirudinsLeechesThrombin

Zusammenfassung

First description of hirudins in a non-hematophagous leech: multiple putative hirudin sequences identified in Whitmania pigra; recombinant expression confirmed thrombin-inhibitory activity for some, while others were hirudin-like factors with negligible thrombin inhibition.

Warum dies für die Hirudotherapie relevant ist

This study investigated the transcriptome of the non-hematophagous leech Whitmania pigra to determine whether it expresses hirudin, the prominent thrombin inhibitor. Researchers successfully identified, cloned, and functionally characterized several putative hirudins, proving that this non-blood-feeding leech does indeed express both active thrombin inhibitors and inactive hirudin-like factors. This provides foundational molecular evidence relevant to understanding the evolutionary biology and biochemical diversity of the leech secretome. However, the study is strictly limited to molecular characterization and in vitro functional assays of recombinant proteins, with no implications for clinical practice or live hirudotherapy.

Zitation

Life without blood: Molecular and functional analysis of hirudins and hirudin-like factors of the Asian non-hematophagous leech Whitmania pigra.

Müller C et al. · Journal of thrombosis and haemostasis : JTH, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.